Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.

Jeremie CalaisShaojun ZhuNader HirmasMatthias EiberBoris HadaschikMartin StuschkeKen HerrmannJohannes CzerninAmar U KishanNicholas G NickolsDavid ElashoffWolfgang P Fendler

Published in: BMC cancer (2021)

UCLA IND#147591 ○ Submission: 02.27.2020 ○ Safe-to-proceed letter issued by FDA: 04.01.2020 UCLA IRB #20-000378 ClinicalTrials.gov Identifier NCT04457245 . Date of Registry: 07.07.2020. Essen EudraCT 2020-003526-23.

Keyphrases

pet ct
prostate cancer
study protocol
randomized controlled trial
radical prostatectomy
positron emission tomography
double blind
clinical trial
open label
squamous cell carcinoma
breast cancer risk